Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-25 @ 2:32 AM
Study NCT ID:
NCT05785767
Status:
RECRUITING
Last Update Posted:
2025-11-21
First Post:
2023-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-30
Start Date Type:
ACTUAL
Primary Completion Date:
2030-03-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-02-05
Completion Date Type:
ESTIMATED
First Submit Date:
2023-03-14
First Submit QC Date:
None
Study First Post Date:
2023-03-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-19
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED